Filer Snapshot

CTI BIOPHARMA CORP

CIK 0000891293. SEC filing timeline plus parsed ownership intelligence from 13F, 13D/G, and Forms 3/4/5 where available.

Entity type

Company

Total filings

2,393

Latest filing

06 Jul 2023

Industry

Pharmaceutical Preparations

Filing-backed research brief

Start with the SEC data that changes for this CIK

Latest signal: SEC filing timeline only. Each card links back to the PortfolioSavvy page where the filing evidence is closest.

Go to filings Save page

Largest parsed holding

—

Populates from the latest parsed 13F information table.

Open holding

13D/G large stake

—

No recent parsed 13D/G stake row for this CIK.

Browse 13D/G

Save this filer page

Create a free account to keep this page in your watchlists. After verification, we will save it automatically and open your saved research list.

Create free account and save this filer Already have an account? Sign in and save it
Source: SEC filing 15-12G

15-12G filed on 06 Jul 2023 for CIK 0000891293.

View source filing
At a glance Names, identifiers, and filing context for this profile. 2 identity fields
SEC industry group
Pharmaceutical Preparations (Office of Life Sciences)
Business address
3101 Western Avenue, Suite 800, Seattle, WA, 98121
EDGAR profile Static EDGAR fields kept behind disclosure so the main profile stays readable. 3 profile fields available
Incorporated in
DE
Fiscal year end
31 December
Former names on EDGAR
CELL THERAPEUTICS INC (to 29 May 2014)

Filer intelligence

What SEC filings say about CTI BIOPHARMA CORP

A compact read of parsed XML filings. 13F, 13D/G, and Forms 3/4/5 are shown separately because they answer different ownership questions.

Save filer

SEC source mix

Counts show available parsed rows, not one combined ownership total.

No XML rows yet
13F portfolio No rows yet

Quarterly institutional portfolio holdings.

13D/G stakes No rows yet

Beneficial ownership and large-stake disclosures.

Forms 3/4/5 No rows yet

Officer, director, and 10% owner holdings or transactions.

No parsed ownership summary yet

We still show the SEC filing timeline below. The intelligence summary will populate when parsed 13F, 13D/G, or Forms 3/4/5 data exists for this CIK.

Latest update

What changed recently for CTI BIOPHARMA CORP

New fact period available

Latest financial period: Q1 2023. Open the source-backed page to inspect the fresh filing or facts context.

Update date

15 May 2023

Page type

Company facts

Latest period

Q1 2023

SEC-backed company facts were refreshed from filings filed on 15 May 2023.

Open company facts Browse recent public updates

Benchmark Context

Benchmark context for this company

CTI BIOPHARMA CORP has a source-backed company facts view where you can compare the latest reported metrics with its own recent history and with peer rankings for the same metric.

Compared with

Start on the facts page for period-to-period context, then open a metric ranking when you want to compare the same reported fact across other SEC-reporting companies.

Why this is notable

Latest financial period: Q1 2023. That gives you a fresh baseline before you compare this company with peers.

  • Latest company facts filing date: 15 May 2023.
  • Peer comparisons stay conservative: same metric, compatible units, latest valid company row only.
  • Open the facts page first if you want the cleanest path to verification.

Benchmark context is only shown where the app has enough comparable SEC-backed data to keep the interpretation honest.

Open company facts Browse metric rankings

SEC filing record

CIK 0000891293 filing coverage

Start with this filing record, then use the linked ownership pages when parsed 13F, 13D/G, Forms 3/4/5, or facts data exists for this CIK.

SEC filings
2,393
First seen
27 Jun 1996
Latest filing
06 Jul 2023
Entity
Company

Observed form types

15-12G EFFECT 4 SC 13D/A S-8 POS POS AM 25-NSE SC TO-T/A 8-K SC 14D9/A +30 more

CIK-linked evidence first

CTI BIOPHARMA CORP SEC filings CTI BIOPHARMA CORP insider transactions CTI BIOPHARMA CORP company facts Open SEC filing index

Industry context: Pharmaceutical Preparations.

Latest Filings

Showing the latest 12 of 1,000 SEC filings for CTI BIOPHARMA CORP.

Open full filing history
15-12G File 000-28386

15-12G

Filing date
06 Jul 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-67906

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-221382

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-41300

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-39385

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-152171

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-200453

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-149982

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-200452

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-149981

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-36038

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
EFFECT File 333-192749

EFFECT filing

Filing date
29 Jun 2023
Reporting date
Not listed
SEC evidence
Open document Open filing
Next action
Verify source filing
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .